Publication: Intracerebral hemorrhage following intravenous thrombolysis in Thai patients with acute ischemic stroke
Issued Date
2012-06-01
Resource Type
ISSN
15322653
09675868
09675868
Other identifier(s)
2-s2.0-84861185258
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Journal of Clinical Neuroscience. Vol.19, No.6 (2012), 799-803
Suggested Citation
Pornpatr A. Dharmasaroja, Sombat Muengtaweepongsa, Junya Pattaraarchachai, Permphan Dharmasaroja Intracerebral hemorrhage following intravenous thrombolysis in Thai patients with acute ischemic stroke. Journal of Clinical Neuroscience. Vol.19, No.6 (2012), 799-803. doi:10.1016/j.jocn.2011.08.035 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/14790
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Intracerebral hemorrhage following intravenous thrombolysis in Thai patients with acute ischemic stroke
Other Contributor(s)
Abstract
In Asia, there is limited information regarding symptomatic intracerebral hemorrhage (ICH) in patients treated with intravenous (iv) recombinant tissue plasminogen activator (rtPA). The aim of this study was to identify independent factors associated with symptomatic ICH following iv rtPA. The study included 192 patients with acute ischemic stroke who were treated with iv rtPA. Baseline characteristics were compared between patients with or without ICH. Symptomatic ICH occurred in 5.7% of patients and asymptomatic ICH in 13.0% of patients. An international normalized ratio (INR) ≥1.0 (odds ratio [OR] = 4.89, p = 0.036), atrial fibrillation (OR = 7.21, p = 0.009) and blood glucose concentration > 8.325 mmol/L (OR = 9.00, p = 0.004), were independent risk factors for symptomatic ICH. Atrial fibrillation (OR = 3.56, p = 0.012) and severe stroke (National Institutes of Health Stroke Scale ≥15; OR = 8.94, p < 0.001) were independent risk factors for asymptomatic ICH. The prevalence of symptomatic ICH following iv rtPA in Thai patients was comparable to previous studies. © 2012 Elsevier Ltd. All rights reserved.